Arrowhead Pharmaceuticals Prices $45 Million Private Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
- Wall St subdued in choppy trade after big bank earnings, chips slide
- Oil prices ease as US-Russia diesel deal hopes offset Middle East attacks
- JPMorgan shares edge lower after third-quarter FICC revenue miss
- Fed’s Waller says US bond yield rise driven by growth, not inflation
- Wells Fargo beats profit estimates despite revenue miss
- Bausch + Lomb names Appio interim CEO as Saunders departs
- Cerebras Systems hits new 52-week low on unlock concerns
- Getty Images to go private via prepackaged Chapter 11 restructuring
- CoreWeave stock drops on insider selling notice
- Sysco calls on Teamsters to end LA strike after economic deal reached
Piper Jaffray Cuts Price Target on Arrowhead Research (ARWR) to $8.00 Following 3Q
August 10, 2016 8:53 AM EDTPiper Jaffray maintained an Overweight rating on Arrowhead Research (NASDAQ: ARWR), and cut the price target to $8.00 (from $13.00), following the company's 3Q earnings report. Arrowhead ended FY3Q:16 with cash of $44.6 million and issued 7.63 million shares at $5.90 per share bringing proforma cash to ~$90 million.... More
Arrowhead Research (ARWR) Tops Q3 EPS by 5c
August 9, 2016 5:09 PM EDTArrowhead Research (NASDAQ: ARWR) reported Q3 EPS of ($0.32), $0.05 better than the analyst estimate of ($0.37). Revenue for the quarter came in at $39.58 thousand versus the consensus estimate of $60 thousand.
For earnings history and earnings-related data on Arrowhead Research (ARWR) click here.
... More


